Molecular Partners Ag ADR (MOLN)

$4.59 -0.10 (-2.24%)
Market Cap 175.23M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,700
Avg Vol 4,942
Day's Range N/A - N/A
Shares Out 40.38M
Stochastic %K 40%
Beta 1.03
Analysts Strong Sell
Price Target $10.62

Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting t...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 44 755 77 00
Fax: 41 44 755 77 07
Address:
Wagistrasse 14, Schlieren, Switzerland
FastRocketTraders
FastRocketTraders Mar. 16 at 5:07 PM
$MOLN resumed form the halt?
0 · Reply
erevnon
erevnon Mar. 16 at 11:21 AM
HC Wainwright & Co. reiterates Molecular Partners $MOLN at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 4:32 PM
Clarity = $1 billion mkt cap $RADX $CATX $MOLN $ATNM $CLRB
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 10:41 PM
$MOLN Q4 '25 Earnings Results & Recap For the full year 2026, Molecular Partners expects total operating expenses of CHF45M, including approximately CHF6M in non-cash effective costs for share-based payments, IFRS pension accounting, and depreciation.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 10:08 PM
$MOLN RSI: 75.00, MACD: 0.1742 Vol: 0.31, MA20: 4.51, MA50: 4.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
briefingcom
briefingcom Feb. 2 at 12:44 PM
$MOLN: Molecular Partners AG presents first imaging and dosimetry data for DLL3-targeting radiotherapy MP0712 at TWC 2026 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260202051144MOLN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 30 at 12:55 PM
$MOLN Current Stock Price: $4.15
0 · Reply
DARKP00L
DARKP00L Jan. 27 at 1:17 PM
$MOLN
0 · Reply
DARKP00L
DARKP00L Jan. 27 at 11:18 AM
$MOLN 06:16 on Jan. 27 2026 HC Wainwright & Co. Initiates Coverage On Molecular Partners with Buy Rating, Announces Price Target of $13 #tradeideas
0 · Reply
TheFinalBet
TheFinalBet Jan. 25 at 2:13 AM
$MOLN
0 · Reply
Latest News on MOLN
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes

Mar 19, 2026, 2:00 AM EDT - 2 days ago

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes

MOLN

Molecular Partners to Hold Three Poster Presentations at AACR 2026

Mar 17, 2026, 4:30 PM EDT - 4 days ago

Molecular Partners to Hold Three Poster Presentations at AACR 2026

MOLN

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

Mar 12, 2026, 4:00 PM EDT - 9 days ago

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

MOLN

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

Feb 26, 2026, 1:00 AM EST - 23 days ago

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

MOLN

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

Feb 2, 2026, 1:00 AM EST - 6 weeks ago

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

MOLN

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 1:00 AM EST - 3 months ago

Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

MOLN

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

Dec 7, 2025, 7:00 AM EST - 3 months ago

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

MOLN

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

Nov 12, 2025, 1:00 AM EST - 4 months ago

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

MOLN

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

Nov 3, 2025, 1:00 AM EST - 4 months ago

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

MOLN

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

Nov 3, 2025, 1:00 AM EST - 4 months ago

Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting

MOLN

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

Oct 30, 2025, 4:00 PM EDT - 5 months ago

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

MOLN

EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Aug 26, 2025, 8:08 AM EDT - 7 months ago

EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

EH MOLN

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

Aug 25, 2025, 4:00 PM EDT - 7 months ago

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

MOLN

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

Jun 22, 2025, 4:00 PM EDT - 9 months ago

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

MOLN

Molecular Partners to cut workforce by a quarter

Jun 10, 2025, 1:58 AM EDT - 10 months ago

Molecular Partners to cut workforce by a quarter

MOLN

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

Jun 10, 2025, 1:00 AM EDT - 10 months ago

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

MOLN

Molecular Partners to Present at Upcoming Investor Conferences

May 19, 2025, 1:00 AM EDT - 10 months ago

Molecular Partners to Present at Upcoming Investor Conferences

MOLN

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Apr 25, 2025, 4:00 PM EDT - 11 months ago

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

MOLN

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Apr 16, 2025, 12:00 PM EDT - 1 year ago

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

MOLN

Molecular Partners to hold three poster presentations at AACR 2025

Mar 25, 2025, 4:00 PM EDT - 1 year ago

Molecular Partners to hold three poster presentations at AACR 2025

MOLN

Molecular Partners Publishes Invitation to Annual General Meeting 2025

Mar 25, 2025, 12:00 PM EDT - 1 year ago

Molecular Partners Publishes Invitation to Annual General Meeting 2025

MOLN

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024

MOLN

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Feb 28, 2025, 1:00 AM EST - 1 year ago

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

MOLN

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Jan 12, 2025, 1:00 PM EST - 1 year ago

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

MOLN

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Jan 12, 2025, 1:00 PM EST - 1 year ago

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

MOLN

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Dec 17, 2024, 4:00 PM EST - 1 year ago

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

MOLN

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Dec 8, 2024, 12:00 PM EST - 1 year ago

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

MOLN

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

MOLN

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

MOLN

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Oct 25, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

MOLN

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Oct 22, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

MOLN

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Oct 22, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

MOLN

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Oct 4, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

MOLN

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

Sep 27, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

MOLN

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

Aug 26, 2024, 4:00 PM EDT - 1 year ago

Molecular Partners Reports H1 2024 Corporate Highlights and Financials

MOLN

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

Jun 17, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

MOLN

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Jun 14, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

MOLN

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

Jun 11, 2024, 1:00 AM EDT - 1 year ago

Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024

MOLN

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024

MOLN

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

May 16, 2024, 4:00 PM EDT - 2 years ago

Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

MOLN

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Apr 29, 2024, 11:00 AM EDT - 2 years ago

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

MOLN

Life Science Cares Launches in Switzerland

Apr 19, 2024, 11:12 AM EDT - 2 years ago

Life Science Cares Launches in Switzerland

MOLN

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

Apr 17, 2024, 11:12 AM EDT - 2 years ago

Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting

MOLN

Molecular Partners Publishes Invitation to Annual General Meeting 2024

Mar 26, 2024, 9:26 AM EDT - 2 years ago

Molecular Partners Publishes Invitation to Annual General Meeting 2024

MOLN

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Mar 14, 2024, 4:00 PM EDT - 2 years ago

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Mar 1, 2024, 4:00 PM EST - 2 years ago

Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Jan 7, 2024, 4:00 PM EST - 2 years ago

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Jan 5, 2024, 4:00 PM EST - 2 years ago

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Dec 14, 2023, 1:00 AM EST - 2 years ago

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Dec 10, 2023, 12:00 PM EST - 2 years ago

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

FastRocketTraders
FastRocketTraders Mar. 16 at 5:07 PM
$MOLN resumed form the halt?
0 · Reply
erevnon
erevnon Mar. 16 at 11:21 AM
HC Wainwright & Co. reiterates Molecular Partners $MOLN at Buy and maintains the price target at https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 13 at 4:32 PM
Clarity = $1 billion mkt cap $RADX $CATX $MOLN $ATNM $CLRB
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 10:41 PM
$MOLN Q4 '25 Earnings Results & Recap For the full year 2026, Molecular Partners expects total operating expenses of CHF45M, including approximately CHF6M in non-cash effective costs for share-based payments, IFRS pension accounting, and depreciation.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 22 at 10:08 PM
$MOLN RSI: 75.00, MACD: 0.1742 Vol: 0.31, MA20: 4.51, MA50: 4.36 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
briefingcom
briefingcom Feb. 2 at 12:44 PM
$MOLN: Molecular Partners AG presents first imaging and dosimetry data for DLL3-targeting radiotherapy MP0712 at TWC 2026 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260202051144MOLN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 30 at 12:55 PM
$MOLN Current Stock Price: $4.15
0 · Reply
DARKP00L
DARKP00L Jan. 27 at 1:17 PM
$MOLN
0 · Reply
DARKP00L
DARKP00L Jan. 27 at 11:18 AM
$MOLN 06:16 on Jan. 27 2026 HC Wainwright & Co. Initiates Coverage On Molecular Partners with Buy Rating, Announces Price Target of $13 #tradeideas
0 · Reply
TheFinalBet
TheFinalBet Jan. 25 at 2:13 AM
$MOLN
0 · Reply
briefingcom
briefingcom Jan. 12 at 1:11 PM
$MOLN: Molecular Partners (+3.8%) highlights clinical development progress and anticipated milestones at 44th Annual J.P. Morgan Healthcare Conference
0 · Reply
FiscalCycleNavigator
FiscalCycleNavigator Dec. 27 at 8:26 AM
$MOLN Momentum persists only for businesses proving consistency quarter to quarter. Forecast reliability has room to improve materially. Credible progress tends to compress risk premiums. Ultimately, disciplined delivery will shape the outcome.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 5:20 PM
$MOLN
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 4:10 PM
JP Morgan has adjusted their stance on Molecular Partners ( $MOLN ), setting the rating to Neutral with a target price of 4 → 3.75.
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 7 at 11:00 PM
$MOLN Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting "Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533"
0 · Reply
bilocelhi
bilocelhi Nov. 12 at 6:40 PM
$QUCY 👀 $MOLN
1 · Reply
bilocelhi
bilocelhi Nov. 12 at 3:45 PM
$MOLN on watch
0 · Reply
topstockalerts
topstockalerts Nov. 3 at 3:48 PM
Top Gainers PT2 $MOLN $NUAI $LGCL $FLUX.X $RNTX
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 27 at 6:25 PM
$MOLN Great piece that accurately captures MOLN's current position. So if you want to refresh your understanding of MOLN or learn about MOLN for the first time, this is essential reading. https://beyondspx.com/quote/MOLN/analysis/molecular-partners-darpin-innovation-powers-oncology-pipeline-nasdaq-moln
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 19 at 8:14 PM
$RADX Molecular Partners has almost triple valuation of Radiopharm Theranostics with less of a pipeline significantly $MOLN
0 · Reply
JarvisFlow
JarvisFlow Sep. 3 at 3:18 PM
JP Morgan updates rating for Molecular Partners ( $MOLN ) to Neutral, target set at 4.5 → 4.
0 · Reply
stockanalysis_
stockanalysis_ Aug. 25 at 10:32 PM
After Hours Losers: $EPIX $ENGN $CAPS $WAI $MOLN https://stockanalysis.com/markets/afterhours/?ref=saveontrading
0 · Reply